top of page
Publications
February 26, 2026
ASCOGU 2026 Trial-in-Progress Poster: KTX-2001 First-in-human Phase 1 STRIKE-001 trial
September 18, 2025
IMS 2025 Poster: International Myeloma Society Poster presentations: Anti-adhesion properties of KTX-1001, a selective NSD2/MMSET inhibitor, enhance Carfilzomib sensitivity in multiple myeloma
IMS 2025 Poster: High Expression of NSD2 in non-t(4;14) newly-diagnosed multiple myeloma patients may mimic t(4;14) biology
December 6, 2025
ASH 2025 Oral Presentation: Phase 1 Study of KTX-1001, a First-in-Class Oral MMSET/NSD2 Inhibitor, Demonstrates Clinical Activity in Relapsed/Refractory Multiple Myeloma
July 2025
Journal of Biological Chemistry: Characterization of the activity of KTX-1001, a small molecule inhibitor of multiple myeloma SET domain using surface plasmon resonance
December 6, 2024
ASH 2024 Trial-in-Progress: First Results from the Dose Escalation Part of the Phase 1 Study of KTX-1001, an Oral, First-in-class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
bottom of page